miRecule™ is a biotechnology company developing RNA therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create …

By combining the technology elements of DREAmiR™, miRecule’s ® ARC’s unlock the true potential of RNA therapies to enable patients live a life free from the debilitating syptoms of …

Oct 4, 2022 · The collaboration will combine miRecule’s anti-DUX4 RNA therapy (discovered through its proprietary DREAmiR platform) with Sanofi’s proprietary muscle-targeted …

Oct 9, 2024 · miRecule and Sanofi have partnered to pioneer innovative approaches in rare diseases and advance a novel RNA therapeutic for patients with the genetic disorder FSHD. …

Therapeutic ProgramsmiRecule, Inc. 704 Quince Orchard Road Gaithersburg, MD 20878

miRecule, Inc. is a rapidly growing biotechnology start-up focused on the development of RNA therapeutics to treat a variety of diseases. miRecule’s DREAmiRTM genomics-based …

Gaithersburg, MD (June 8, 2021) – miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced the hiring of Fu-An …

Dr. John Lambert, Ph.D is one of the leading experts in the field of ADC discovery and development. He joined ImmunoGen in 1987 and served as Chief Scientific Officer from 2008 …

Personal information provided to miRecule through resumes, CVs, or cover letters is provided through an applicant’s own volition. Any information provided (email, phone number, etc.) will …

miRecule, Inc. is a rapidly growing biotechnology start-up focused on the development of RNA therapeutics to treat a variety of diseases. miRecule’s DREAmiR genomics-based discovery …